Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Published:2024-05-15 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Ai Jiahuan^ORCID,Jian Liuying,Wen Xiaoqin,Huo Xiaotong,Yang Xuanyi,Jiang Jie,Zhang Tiantian

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03506-4.pdf

Reference48 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 CANCERS in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.

4. Ma C, Ye D, Li C, Zhou F, Yao X, Zhang S, et al. Epidemiologic characteristics of prostate cancer and analysis of first-line endocrine therapy in advanced stage. Chin J Surg. 2008;12:921–5.

5. Zhu Y. Expert consensus on the diagnosis and treatment of denervation-resistant prostate cancer in China. Chin Surg Miscell J. 2016;54(7):481–4.